As we observe 2° effector CD8+ T cells to have a reduced proliferative response, particularly in chronic, low antigen settings, we speculate that effective T cell vaccines for tuberculosis will need to elicit high affinity TCRs and respond earlier than the primary response to infection. The gene discussed is CD8A; the disease is tuberculosis.